Skip to main content
Premium Trial:

Request an Annual Quote

NCI Seeks Molecular Signature Partnerships

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The National Cancer Institute intends to support research partnerships focused on molecular signatures from cancer tumors that can be used in developing new clinical tools for disease treatment.

The "Strategic Partnering to Evaluate Cancer Signatures" program aims to generate data sets and publications that the scientific community may use to develop, design, and conduct future clinical trials that use multi-analyte signatures in cancer treatments.

These signatures could be based on gene or microRNA expression, or genomic alterations such as DNA amplifications, deletions, translocations, mutations, single nucleotide polymorphisms, epigenetic events, or protein expression.

NCI said in a request for applications that there is "growing recognition" among clinical cancer researchers that using data about molecular alterations at the levels of DNA, RNA, and protein may offer "a significant opportunity" for developing new clinical cancer treatments.

The goal of this program is to support strategic partnerships that will involve multi-disciplinary expertise and resources to discover how information from molecular analyses can be used to improve patient care and outcomes.

Researchers may use the partnerships that investigate questions on a range of areas, including but not limited to how molecular signatures can be used in: prediction of response to targeted therapies; prognosis for the patient at the time of the diagnosis; risk of progression in early-stage disease; identification of subsets within a tumor classification, stage, or grade where there is known heterogeneity in clinical behavior, including response to treatment with standard drugs or radiation therapy.

NCI has not set aside a certain amount of funding for the program, and the support it may provide will depend on research proposals and on available resources.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.